NCT05253118View on ClinicalTrials.gov

Relapsed or Refractory Primary Diffuse Large B-cell Lymphoma (DLBCL) of the Central Nervous System (CNS)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

August 18, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

February 28, 2026

Conditions
DLBCL
Interventions
DRUG

Tislelizumab

Tislelizumab (BGB-A317) 200mg will be administered on Day 1 of each 21-day cycle (once every 3 weeks) in combination with pemetrexed.

DRUG

Pemetrexed

Pemetrexed 500 mg/m2 will be administered on Day 1 of each 21-day cycle (once every 3 weeks).

Trial Locations (1)

03080

Seoul National University Hospital, Seoul

All Listed Sponsors
collaborator

Gyeongsang National University Hospital

OTHER

collaborator

Kyunghee University Medical Center

OTHER

collaborator

Inje University Haeundae Paik Hospital

OTHER

collaborator

Chungnam National University Hospital

OTHER

lead

Seoul National University Hospital

OTHER